Scancell Holdings plc (AIM: SCLP)

London flag London · Delayed Price · Currency is GBP · Price in GBX
9.80
-0.25 (-2.49%)
Jan 20, 2025, 4:37 PM GMT+1
-8.84%
Market Cap 89.71M
Revenue (ttm) n/a
Net Income (ttm) -5.86M
Shares Out 929.60M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 67,911
Average Volume 1,546,515
Open 10.00
Previous Close 10.05
Day's Range 9.60 - 10.00
52-Week Range 8.60 - 19.75
Beta 0.42
RSI 36.93
Earnings Date Jan 24, 2025

About Scancell Holdings

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 61
Stock Exchange London Stock Exchange AIM
Ticker Symbol SCLP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.